SCHEMBL6782255

SCHEMBL6782255

Fc1cccc(-c2cccc3c2C2CCNCCC2N3)c1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PLAT P00750 1/20 0.39
HTR1A P08908 3/20 0.36
SLC6A2 P23975 3/20 0.36
SLC6A4 P31645 3/20 0.36
SLC6A3 Q01959 3/20 0.36
WNT1 P04628 1/20 0.35
TGFBR1 P36897 1/20 0.35
HTR7 P34969 3/20 0.35
ADRA2A P08913 1/20 0.34
ADRA2B P18089 1/20 0.34
ADRA2C P18825 1/20 0.34
MAP4K3 Q8IVH8 1/20 0.34
NISCH Q9Y2I1 1/20 0.34
LMNA P02545 1/20 0.34
TSHR P16473 1/20 0.34
CHRM1 P11229 1/20 0.34
CHRM3 P20309 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6782257 1.00 PLAT (0.39) PLATHTR1ASLC6A2SLC6A4SLC6A3
SCHEMBL6785280 0.91 CHRM3 (0.35) PLATHTR1ASLC6A2SLC6A4SLC6A3
SCHEMBL6785282 0.91 CHRM3 (0.35) PLATHTR1ASLC6A2SLC6A4SLC6A3
SCHEMBL6785602 0.87 HTR7 (0.40) PLATHTR1ASLC6A2SLC6A4SLC6A3
SCHEMBL6785604 0.87 HTR7 (0.40) PLATHTR1ASLC6A2SLC6A4SLC6A3
SCHEMBL6785250 0.86 CREBBP (0.42) WNT1LMNATSHRCHRM1CHRM3
SCHEMBL6785254 0.86 CREBBP (0.42) WNT1LMNATSHRCHRM1CHRM3
SCHEMBL6790774 0.86 BRD4 (0.40) HTR1ASLC6A2SLC6A4SLC6A3HTR7
SCHEMBL6790777 0.86 BRD4 (0.40) HTR1ASLC6A2SLC6A4SLC6A3HTR7
SCHEMBL6790499 0.85 HTR2C (0.41) HTR1AHTR7ADRA2AADRA2BADRA2C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6828314-B2 Modulation of the activity of serotonin receptors (5-HT) to treat diseases such as anxiety, depression or obesity PFIZER 2004-12-07 US disclosed
US-20030225058-A1 Substituted azepino[4,5b]indoline derivatives PHARMACIA & UPJOHN COMPANY 2003-12-04 US disclosed
US-6586421-B2 For therapy of central nervous system, including diseases, disorders, and conditions related to, such as anxiety, depression, hypertension, migraine, obesity, compulsive disorders, schizophrenia, autism, neurodegenerative disorders PHARMACIA & UPJOHN COMPANY 2003-07-01 US disclosed
US-20020077318-A1 Substituted azepino[4,5b] indoline derivatives PHARMACIA & UPJOHN COMPANY 2002-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225058-A1 Substituted azepino[4,5b]indoline derivatives HTR5A, HTR1A, HTR4 PLAT 4403/4885HTR1A 2/4885SLC6A2 104/4885
US-20020077318-A1 Substituted azepino[4,5b] indoline derivatives HTR5A, HTR1A, HTR4 PLAT 4403/4885HTR1A 2/4885SLC6A2 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.